Suven Life Sciences Yönetim

Yönetim kriter kontrolleri 2/4

Suven Life Sciences CEO'su Venkat Jasti, Oct2004 tarihinde atandı, in görev süresi 20.08 yıldır. şirketin hisselerinin 0.001% doğrudan sahiptir ve bu hisselerin değeri ₹ 258.69K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 14.2 yıl ve 10.5 yıldır.

Anahtar bilgiler

Venkat Jasti

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	20.1yrs
CEO sahipliği	0.001%
Yönetim ortalama görev süresi	14.2yrs
Yönetim Kurulu ortalama görev süresi	10.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Venkat Jasti'un ücretlendirmesi Suven Life Sciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-₹1b
Jun 30 2024	n/a	n/a	-₹1b
Mar 31 2024	n/a	n/a	-₹1b
Dec 31 2023	n/a	n/a	-₹1b
Sep 30 2023	n/a	n/a	-₹1b
Jun 30 2023	n/a	n/a	-₹1b
Mar 31 2023	n/a	n/a	-₹1b
Dec 31 2022	n/a	n/a	-₹1b
Sep 30 2022	n/a	n/a	-₹940m
Jun 30 2022	n/a	n/a	-₹991m
Mar 31 2022	n/a	n/a	-₹1b
Dec 31 2021	n/a	n/a	-₹1b
Sep 30 2021	n/a	n/a	-₹1b
Jun 30 2021	n/a	n/a	-₹1b
Mar 31 2021	n/a	n/a	-₹722m
Dec 31 2020	n/a	n/a	-₹761m
Sep 30 2020	n/a	n/a	-₹745m
Jun 30 2020	n/a	n/a	-₹787m
Mar 31 2020	n/a	n/a	-₹942m
Dec 31 2019	n/a	n/a	₹28m
Sep 30 2019	n/a	n/a	₹1b
Jun 30 2019	n/a	n/a	₹871m
Mar 31 2019	₹58m	₹29m	-₹239m
Mar 31 2018	₹47m	₹25m	₹1b

Tazminat ve Piyasa: Venkat şirketinin toplam tazminatının Indian pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Venkat şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Venkat Jasti (75 yo)

20.1yrs

Görev süresi

Mr. Venkateswarlu Jasti, also known as Venkat, M.Pharm. M.S., has been the Managing Director and Executive Chairman of the Board of Suven Life Sciences Limited since November 01, 2024. He is Member of Advi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Venkateswarlu Jasti	CEO, MD & Executive Chairman	20.1yrs	Veri yok	0.0010% ₹ 258.7k
Sudharani Jasti	Whole-Time Director	35.7yrs	₹9.99m	0.70% ₹ 179.5m
M. Kumar	Chief Financial Officer	4.8yrs	Veri yok	Veri yok
Kundan Jha	Company Secretary & Compliance Officer	less than a year	Veri yok	Veri yok
Kalyani Jasti	President of US Operations	14.2yrs	Veri yok	0.00046% ₹ 117.8k

14.2yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim: 530239 'un yönetim ekibi deneyimli ve deneyimlidir ( 14.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Venkateswarlu Jasti	CEO, MD & Executive Chairman	35.7yrs	Veri yok	0.0010% ₹ 258.7k
Sudharani Jasti	Whole-Time Director	35.7yrs	₹9.99m	0.70% ₹ 179.5m
Seyed Hasnain	Non-Independent & Non-Executive Director	14.6yrs	₹200.00k	Veri yok
Santanu Mukherjee	Independent Non-Executive Director	6.5yrs	₹250.00k	Veri yok
Jasthi Ananthasai Padmaja	Independent Non-Executive Director	6yrs	₹110.00k	Veri yok
Vajja Rao	Independent Director	less than a year	Veri yok	Veri yok

10.5yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 530239 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.5 yıldır).

Suven Life Sciences Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Suven Pharma Announces Board Changes

Suven Life Sciences Limited Announces Step Down of Vaidheesh Annaswamy as Executive Chairperson and Director

Suven Life Sciences Limited, Annual General Meeting, Aug 02, 2024

Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024

Suven Pharma Appoints Sudhir Kumar Singh as CEO

Suven Life Sciences Limited, Annual General Meeting, Aug 05, 2023

Recent updates

New major risk - Financial position

Second quarter 2025 earnings released: ₹2.27 loss per share (vs ₹0.58 loss in 2Q 2024)

Suven Life Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024

Suven Pharma Announces Board Changes

Suven Life Sciences Limited Announces Step Down of Vaidheesh Annaswamy as Executive Chairperson and Director

Suven Life Sciences Announces Positive Topline Results from Phase-2A Proof-Of-Concept Signal Detection Open Label Study of Ropanicant (Suvn-911) for the Treatment of Moderate to Severe Major Depressive Disorder

Suven Life Sciences Announces FDA Acceptance of Investigational New Drug (IND) and Grant of Study May Proceed Letter to Initiate Phase-1 Clinical Trial of SUVN-I6107

New minor risk - Share price stability

First quarter 2025 earnings released: ₹1.29 loss per share (vs ₹1.10 loss in 1Q 2024)

Suven Life Sciences Limited to Report Q1, 2025 Results on Aug 05, 2024

Full year 2024 earnings released: ₹4.82 loss per share (vs ₹6.63 loss in FY 2023)

Suven Life Sciences Limited, Annual General Meeting, Aug 02, 2024

Full year 2024 earnings released: ₹4.82 loss per share (vs ₹6.63 loss in FY 2023)

Third quarter 2024 earnings released: ₹1.92 loss per share (vs ₹2.90 loss in 3Q 2023)

Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024

Suven Life Sciences Limited to Report Q3, 2024 Results on Jan 30, 2024

New major risk - Share price stability

Suven Life Sciences Limited to Report Q4, 2024 Results on May 15, 2024

Second quarter 2024 earnings released: ₹0.58 loss per share (vs ₹1.59 loss in 2Q 2023)

New minor risk - Share price stability

Suven Life Sciences Limited to Report Q2, 2024 Results on Nov 04, 2023

Suven Pharma Appoints Sudhir Kumar Singh as CEO

Suven Life Sciences Limited to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings released: ₹6.63 loss per share (vs ₹9.05 loss in FY 2022)

Suven Life Sciences Completes Enrollment of Patients to the Phase-2, Proof of Concept Clinical Study of Samelisant (SUVN-G3031) for the Treatment of Narcolepsy with or Without Cataplexy in USA and Canada

Suven Life Sciences Limited, Annual General Meeting, Aug 05, 2023

Full year 2023 earnings released: ₹6.63 loss per share (vs ₹9.57 loss in FY 2022)

Third quarter 2023 earnings released: ₹2.90 loss per share (vs ₹2.65 loss in 3Q 2022)

Suven Life Sciences Limited to Report Q3, 2023 Results on Feb 02, 2023

Suven Life Sciences Limited Announces the Randomization of First Patient in the Phase-3 Global Clinical Trial of Masupirdine for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type

Price target decreased to ₹306

Insufficient new directors

Second quarter 2023 earnings released

Suven Life Sciences Limited to Report Q2, 2023 Results on Nov 08, 2022

Suven Life Sciences Limited Declares Special Dividend for the Financial Year 2022-23, Payable on and from September 20, 2022

Suven Life Sciences Limited to Report Q1, 2023 Results on Jul 26, 2022

Full year 2022 earnings released: ₹9.57 loss per share (vs ₹5.67 loss in FY 2021)

Suven Life Sciences Limited Declares One-Time Special Dividend for the Financial Year 2021-22, Payable on and from 25 May, 2022

Full year 2022 earnings released: ₹9.57 loss per share (vs ₹5.67 loss in FY 2021)

Suven Life Sciences Limited, Annual General Meeting, Aug 04, 2022

Suven Life Sciences Limited to Report Q4, 2022 Results on May 07, 2022

Price target decreased to ₹306

Insufficient new directors

Suven Life Sciences Limited Declares Interim Dividend, Payable on and from 22 February 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: ₹2.22 loss per share (vs ₹1.23 loss in 2Q 2021)

Price target decreased to ₹306

Full year 2021 earnings released: ₹5.67 loss per share (vs ₹7.40 loss in FY 2020)

Price target increased to ₹472

Full year 2021 earnings released: ₹5.67 loss per share (vs ₹7.40 loss in FY 2020)

Suven Life Sciences Limited announced that it has received INR 369.10425 million in funding from Jasti Family Trust

Independent Non-Executive Director has left the company

Third quarter 2021 earnings released: ₹1.92 loss per share (vs ₹1.79 loss in 3Q 2020)

Suven Life Sciences Limited to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: ₹57.90

First half earnings released

New 90-day high: ₹56.45

Insider recently bought ₹1.0m worth of stock

New 90-day high - ₹54.50

Suven Life Sciences Limited to Report Q1, 2021 Results on Aug 17, 2020

First quarter earnings released

New 90-day high - ₹48.55

Suven Life Sciences Limited to Report Q1, 2021 Results on Aug 11, 2020

Price target raised to ₹537

Suven Life Sciences Limited(BSE:530239) dropped from S&P Global BMI Index

CEO Tazminat Analizi

CEO